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Commentary I
Nongenotoxic Carcinogens: An Extension of
the Perspective Provided by Perera
by J. Ashby1 and I. H. Purchase1
Pererarecentlydiscussed the veryreal problems that accompany anyattempttoclassify rodentcarcinogens
into two groups-genotoxic or nongenotoxic. Not the least of these problems is that no agreed definition of
these two terms exist. Nonetheless, the current carcinogen databases, for example, that ofthe U.S. National
Toxicology Program (NTP), clearly comprise two broad groups ofcarcinogens-DNA reactive, mutagenic and
multiply carcinogenic chemicals, and others. The others appear to be nonreactive to DNA, are inactive in the
primary mutagenicity assays, andusually elicit highly selective carcinogenic responses in animals.These two
classes ofcarcinogen are illustrated by examples taken from the NTP database and are discussed within the
possible context ofthe latter group not being active in humans or, ifthey are, only when a threshold dose has
been exceeded, chronically.
Perera (1) recently discussed uncertainties associated
withthecategorization ofrodentcarcinogensforpurposes
of risk assessment, according to their presumed mecha-
nism of action-genotoxic or nongenotoxic. These uncer-
tainties call into question automatic secondary assump-
tions such as that nongenotoxic carcinogens operate only
above a certain threshold dose and are ofreduced hazard
to humans. Perera concluded her analysis by stating that,
in light of these uncertainties and in the absence of
evidence to the contrary, there is currently no convincing
scientificrationaleforassigning agreaterorlesserdegree
of risk to carcinogens based on their presumed mecha-
nism or stage ofaction (1). The direct consequence ofthis
conclusionisthatallrodentcarcinogens mustberegarded
asposing anequalhazard tohumans once adjustmenthas
beenmadeforthedifferingdoselevelsusedinthedefining
rodent bioassays.
Much ofwhatPererawrote couldbejustifiedbythefact
that to date no single definitions of the terms "non-
genotoxic" or "tumor promoter" have emerged. In the
absence ofsuch agreed definitions it could be argued that
it is pointless to proceed further. Set against that view-
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point is the one held by many investigators that non-
genotoxic mechanisms of carcinogenicity are strongly
indicated but imperfectly established at present (2-4).
Further, it would be expected that some nongenotoxic
mechanisms ofcarcinogenicityinrodentsmaynotapplyto
humansandthatsomemaybethresholdrelated.Thelatter
viewpoint currently acts as the stimulus for much basic
research and is therefore worthy of equal consideration.
Probably the leastuseful exercise to attempt at present
is a definition of the term "nongenotoxic." Rather, it is
worth defining areas of common assent and identifying
areas of apparent disagreement, the latter ofwhich usu-
ally turn out to be areaswhere data are missing, which in
turn allows opinions to dominate.
Ifthere is any common ground, it must be that the first
five rodent carcinogens shown in Table 1 are not only
genotoxic but that their genotoxicity is mechanistically
related to their rodent carcinogenicity. The first two of
these carcinogens are active at the site ofinitial contact in
the rodents, and they are each active in both sexes ofboth
species. It therefore seems probable that similar effects
would be observed in humans exposed to these chemicals,
and further, that compelling data would be required to
counter the assumption ofthe absence ofa threshold dose
level. These two examples thereforeprovide aperfect case
for risk estimation, i.e., one could calculate a cancer inci-
denceof, say, 1 in106inmanandbeasconfidentaseverone
lr- n I224 ASHBYAND PURCHASE
Tlable 1. Carcinogenicity data for BWC3F mice and F344 rats, as reported by NTP and extracted by Ashby and Tennant (5) a
GAS No Tumor data identified in Summary of NTP Technical Report
NTP Tech Report No (Year) Salmonella Maximum % Tumor_bearing_animals
Chemical Structure Structural ausay Route dose (ppm)RasMc
(alerting substructure in Sold) alert response Tumor ______as____Mc
Rats Mice site Male Female Male Female
ChemicalName (Zeiger) C L IH C L IH C L IH C 7L H
106-87-6
362) t989)
0 ~~~~~~~~~~~~~~~C L M H C L M H
00 % ~~+ + Skin 30mg/ ro0mg/ Skin 0 66 72 0 32 69 0 2978984 5 t2 74 82
ofl CHf-NCH2 animal animal Ovary 2 0 35 36 1: F ~~~~~~ ~ ~ ~~~~~~~~~Lung 181 21
4-Vinyl-t1-cyclohexene Diepoxode
509-ta-8
396 )t990)
NO2
I + + Inhalation 0.0005 0.0002 Lung 2 66 92 0 44 tOO 24 52 92 9 a8 98
02N-C- NO2
NO2
Tetranitromethane
39156-41-7
8.4(1978) NH2 C C,L i4 C,C,L H C,C,L HeC C. L H
Clitoral gland 0 6 to t6
+ + Food 0.5 0.24 Preputial gland 0 0 a t6 Skin 0 0 4 t4
Thyroidgland 6 04 305 2 2202 0 024 0 00 19
NH2 ~~~~~~~~~~Zymbal'sgland 0 0 2 t6 0 0 0 1d
OCH3
2,4-Diaminoanisole Sultate
602-87-9 C C,,L H C,C, L H C L H
118)1978) Clitoral gland 0 0 13 13
- - ~~~~~~~~~~~~~~~~~~~~~~Liver caromn. 4 49 95
+ + Food 0.24 0.12 Lung O 2t14O 0 2t17t0 - - ~~~~~~~~~~~~ ~ ~~~~~~~~~~Mammary gland 0 0 ti 16
Ovary 0 tO 19
Skin 2 0 0043 0 0 5074
5-Nrtroacenaphthene NO
107-06-2
55)1978) C1C Li-I C,CL H C, C L HC, Cit H
Circalatory 2 0 98 td
CCH H2+ + Ovg 0 29 Lang 0 02 31 30 14 31 2IH
aae 9 9 Mammrarygand 0 6 2 02 36 0 0 98 tO
CI C Subcutaneous 0 010 12
Uterus 0 o to tt
12-Dichloroethane______L
103-23-1
212)t982)
7C02CH2CH(Et)(CH2)3CH3 - -
Food 2.5 2.5 Liver adenomas 26
at 50 6 39 37
(CH2)4 Liver carcin. 2 28 24
~C02CH12CH(EtCH23CH3
Di)2-ethyIhexy1)adipate
2432-99-7
216)t1992)
- - ~~~~~Food 1.5 1,5 Liveradenomas 2 t9 t6 H2N - (CH2)1oC02H Urinary bladder 0 0 14
tAminoundecanoic Acid
98-85-1
369)1999) OH
0u -- -3OGvage 750 700 Kidney 0 4 to
nx-Methylbenzyi Alcohol
too-so-s
149)1979)
S
11~ ~ ~ ~ Food 0~025 0.05 Thyroid gland 0 2 23 0 9 37
EtNH -C- NHEt
N.N-Diethylthiourea
5989-27-5
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H2C!#C 'CH3
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FIIIII~~~JI + + Food Non-carcinogenic
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Abbreviations: C, control; L, low-dose groups; M, mid-dose groups; H, high-dose groups; Cp, pooled controls.
aThe duration of the negative study was 103 weeks.NONGENOTOXIC CARCINOGENS
can be that such an incidence ofinduced cancer could be
detected by an appropriately sensitive epidemiological
study.
Similar argumentswould applytothe nextthree rodent
carcinogens in Table 1, albeit an element ofuncertainty is
caused in these cases by the seemingly random spread of
affected tissues. However, genotoxic carcinogenesis is far
from understood atthe level oforganotropic responses, so
such concerns remain minor. In summary, the first five
carcinogens shown in Table 1, which are representative of
the majority of the National Toxicology Program (NTP)
carcinogen database, can be safely assumed to present a
commensurate carcinogenic hazard to man. These five
carcinogens were selected because they are active in all
four test groups and atboth thelowand the high bioassay
doselevels [thiswas donetoeliminatefromthis discussion
the important but secondary issues of species-specific
metabolism or high-dose toxicity influencing carcino-
genicity (5)]. The genotoxic noncarcinogen shown at the
bottom ofTable 1 was also included to introduce and then
to dismiss from this discussion the concept of genotoxic
noncarcinogens (4).
Thesecondsetoffiverodentcarcinogens showninTable
1 is also from the NTP carcinogen database and was
selected to illustrate the type of agent currently (albeit
sometimes loosely) referred to as nongenotoxic car-
cinogens. The impression given by these five carcinogens
is that they are grossly different from the first five. In
particular, the prospect is raised that the biological
activities of these agents in the tissues subject to their
selective carcinogenicity are probably a stronger lead to
theircarcinogenicitythan is anyselective DNAdamaging
(genotoxic) activitiestheymayunexpectedlyshowinthose
tissues. Inparticular, evenintheabsence ofanymechanis-
ticdata, onewouldbelessconfidentthanwiththefirstfive
carcinogens inpredicting ahuman cancerincidence of1 in
106 for people exposed to low dose levels of limonene, for
example. It is suggested that this gross feeling is the
primary stimulus for studies into the mechanism of non-
genotoxic carcinogens-it cannotbeprecisely defined, but
it would probably be negligent to ignore such a strong
indication. Infact,mechanisticdataexist,invarious stages
of refinement, to support possible alternative (non-
genotoxic) mechanisms of action for these agents (2).
Havingfailed to define the term nongenotoxic herein, it
is necessary to address the obvious counter arguments at
this point. Although classed as structurally nonalerting,
the second five carcinogens shown in Table 1 may contain
hitherto unrecognized electrophilic centers. Further,
although nonmutagenic to Salmonella, they will probably
beactiveinoneorotheradditionalinvitromammaliancell
genotoxicity assays (all chemicals are active, without
exception, when a sufficient number of tests have been
conducted). Finally,eachchemical maydirectlymodifythe
DNAoftheaffectedtissues. These counter arguments are
accepted as possible, but they do not appear to be strong
enough to suggest that the 10 carcinogens in Table 1
representamechanistic continuum.Theonlypointmadeis
thatitseems curious thatthose carcinogens that are most
selective in their carcinogenic activity should also be the
ones that have novel electrophilic sites and subtle geno-
toxic activities.
If it is accepted as possible that a mechanistic gulf
separates the first five carcinogens in Table 1 from the
secondfive, thenthereis anurgentneed tofocus research
to answer the questions posed orimplied byPerera (1), as
follows.
First is the need for at least one agreed precedent for
each of the several classes of nongenotoxic carcinogens.
For example, progress in the study of peroxisome pro-
liferators (e.g., thehepaticcarcinogen shownsixthinTable
1) is being slowed by each of the major research groups
studying a different member of the class. This delays
overall progress and complicates comparison of data. A
similar situation exists in the study of male rat renal
carcinogens operating via the a-2-microglobulin mecha-
nism. Selection of a single agent for joint study in each
class of nongenotoxic carcinogen is therefore suggested.
Second, if an agent is to be considered as a possible
nongenotoxic carcinogen, it should first be evaluated for
genotoxicity in the standard genetic toxicity assays. At
presentthisneed isusuallyneglected. Thus, dimethylpen-
tane, a renal carcinogen associated with a-2-
microglobulin, is devoidofanypublished genotoxicity data
despite the advanced stage of mechanistic studies on it.
Likewise, few bone marrow cytogenetic assay data have
been reported for the peroxisome proliferators and none
forthemale ratrenal carcinogen limonene. The activityof
a presumed nongenotoxic carcinogen in a genotoxicity
assaydoes notautomaticallyexcludeanongenotoxicmech-
anism of carcinogenic action, but such data should be
available for consideration.
Thirdistheurgentneedtodemonstrateunequivocallya
threshold effect for at least one presumed nongenotoxic
carcinogen. Such a carcinogenicity bioassay could be con-
ducted in a single sex ofa single species, but itwould have
to be designed such that agreement was obtained in
advance regarding its statistical resolving power. If an
acute precursor event is known to be directly involved in
thecarcinogenicity ofthe agentselectedforstudy,thresh-
old studies could be related initially to that event, much as
Swenberg and his colleagues (6) have donewhen studying
the mechanism ofaction oflimonene as arenal carcinogen
using renal foci promotion studies. However, some knowl-
edge of the relevance of the precursor event to car-
cinogenicitywould be necessary. The threshold studies by
Lucier and Portier (7) on TCDD illustrate both the prom-
ise and the potential complexity of this approach (the
extreme and unrepresentative metabolic stability of
TCDD confuses further the threshold issue in this case).
At present, however, there are no statistically sound data
on thresholds in nongenotoxic carcinogenesis.
A particularly illuminating example of how debates on
nongenotoxic rodent carcinogenesis can become confused
bysecondaryissuesisprovidedbytheU.S. Food andDrug
Administration (FDA) consideration of the case of the
color FD&C No. 3 (8). This chemical induces follicular cell
tumors in male Charles River CD-1 rats when dosed at a
concentration of4% in the diet. From the detailed discus-
sion provided in the U.S. Federal Register (8), it becomes
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clearthattheextensive evidenceavailableisinfavorofthis
chemical being carcinogenic byvirtue ofhyperstimulation
ofthe thyroid, ratherthanbyitdirectly damagingthyroid
cell DNA. However, thiswell-developed argument in favor
ofa nongenotoxic mechanism ofaction was confused, and
finallyrejected, based on two secondary issues: a) discus-
sion ofwhether the agent is trulyinactive in the available
genetic toxicity assays and b) whether a threshold dose
had been established forthe thyroid effects. The concerns
expressedbythe FDAonthesetwo secondaryissueswere
justified. What seems to be unjustifiable was that the
short-term need to be able to register this agent as being
absolutelywithout ahuman carcinogenic hazard obscured
the wealth ofdata supporting a nongenotoxic mechanism
ofrodentcarcinogenicity. Giventhestrength ofthismech-
anistic data, the question of whether FD&C No. 3 is
inactive in the genotoxicity assays conducted becomes
almost irrelevant. For example, even if more extensive
repeat tests conducted in the mouse lymphoma L5178Y
assay were to uncover a positive test response, it seems
unlikely that this would affect the conclusion of a non-
genotoxicmechanismofthyroidcarcinogenicity. Likewise,
further datamayunequivocallyestablish athreshold dose
for the hormonal and carcinogenic thyroid effects
reported,buttheabsenceofsuchdatadoesnotweakenthe
central strongimplication ofanongenotoxic mechanism of
carcinogenic action.
There arethereforetwoalternative positions toadoptin
response to the 10 carcinogens shown in Table 1. The first
is to assume that each is of similar hazard to man. The
secondis to consider each carcinogen withinthe contextof
its total biology and to assess the extent to which its
carcinogenicity mayapply to humans. Consideration ofall
of the available data will usually enable the agent to be
classified tentatively as operating by a genotoxic or a
rongenotoxic mechanism. Once a possible nongenotoxic
mechanism is indicated, further studies become justified
to studythe relevance ofits carcinogenicityto man and/or
the possible existence of a threshold dose.
The term "nongenotoxic carcinogen" therefore holds a
similar position to that held bytheword "evolution" in the
1890s when the Marquis of Salisbury defined it as "an
indefinite word which has the gift of alleviating so many
perplexities andmasking somanygaps in ourknowledge"
(9).Atpresentitsmainuse,whileremainingtentative,isto
aidpriority settingin carcinogen detection andregulation
(10,11), as recently discussed byGoodman andWilson (12).
Goodman and Wilson (12) actually extended this present
discussion by suggesting that chemicals should not be
classified as carcinogens and noncarcinogens, but rather
that we should assume all chemicals are carcinogenic and
that some have too low apotency toproduce a statistically
significant increase in tumors with a given experimental
protocol. That proposal was discussed by Goodman and
Wilson (12)within the single contextofpotency, butamore
general validity may be established by evaluating the
present NTP noncarcinogens in awidervariety ofrodent
species and strains. Thus, acharacteristic ofnongenotoxic
carcinogenesis tissue bioassays is that they tend toward
species/strain/sex/tissue specificity (4), so the greater the
amount of different bioassays conducted on a noncar-
cinogen, presumably the greater will be the chance of an
isolated carcinogenic responsebeingobserved. However,if
one first dissolves the boundary between genotoxic and
nongenotoxic carcinogens (1) and then the one between
carcinogens and noncarcinogens (12), lable 1 becomes a
continuum ofhazardous chemicals. Ifto this is added the
counsel ofperfection that we should "consider the multi-
plicity of action of a single agent and the influence of all
agents to which humans are exposed simultaneously" (1),
then any practical steps toward carcinogenic regulation
are proscribed.
Itisthereforeproposed thattheterms"genotoxic"* and
"nongenotoxic" carcinogen should be maintained and
refined in the causes of research into mechanisms of
carcinogenicity(13,14) and ofefficienthumancarcinogenic
hazard assessment. For the present this is subjectively
supportedbythesuggestion thatanysystemthatfails, for
example, to accord tetranitromethane (Tlable 1) an intrin-
sically higher (i.e., dose independent) potential human
hazard ratingthatlimonene (Tlable 1) mustbe regarded as
deficient. Nonetheless, the reservations expressed by Per-
era (1) arevalid andtherefore use ofthese termsmust, for
the present, remain tentative.
*Practical methods to screen for genotoxins are discussed by Ashby
and Morrod (3).
REFERENCES
1. Perera, F. P. Perspectives on the risk assessment for nongenotoxic
carcinogens and tumor promoters. Environ. Health Perspect. 94:
231-235 (1991).
2. Hildebrand, B., Ed. Earlyindicators ofnon-genotoxic carcinogenesis.
Mutat. Res. (special issue) 248: 211-374 (1991).
3. Ashby J., and Morrod, R. S. Detection ofhuman carcinogens. Nature
352: 185-186 (1991).
4. Ashby,J., andTennant, R.W. Definitive relationships amongchemical
structure, carcinogenicity andmutagenicity for301 chemicals tested
by the U.S. NTP. Mutat. Res. 257: 229-312 (1991).
5. Ames, B. N., and Gold, L. S. Too many rodent carcinogens. Science
249: 970-971 (1990).
6. Dietrich, D. R., and Swenberg, J. A. Preneoplastic lesions in rodent
kidney induced spontaneously or by non-genotoxic agents. Mutat.
Res. 248: 239-260 (1991).
7. Roberts, L. More pieces in the dioxin puzzle. Science 254: 377 (1991).
8. Color additives: denial ofpetition. Fed. Reg. 55: 3520-3543 (1990).
9. Marquis ofSalisbury. Evolution, aRetrospect. The Roxburghe Press,
London, 1894, p. 25.
10. Doll, R., andPeto, R. The Causes ofCancer. Oxford University Press,
London, 1981.
11. Ames, B. N., and Gold, L. S. Responseto "Carcinogenic risk assess-
ment." Science 240: 1045-1047 (1988).
12. Goodman, G., andWilson, R.Predictingthe carcinogenicity ofchemi-
cals in humans from rodentbioassay data. Environ. Health Perspect.
94: 195-218 (1991).
13. Sutter, T. R., Guzman, K., Dold, K. M.,andGreenlee, W. F. Targetsfor
dioxin: genes for plasminogen activation inhibitor-2 and interleukin-
13. Science 254: 415-418 (1991).
14. Issemann, I., and Green, S. Activation of a member of the steroid
hormone receptor superfamily by peroxisome proliferators. Nature
347: 645-650 (1990).